Sanofi has sold a 50% controlling stake in its consumer healthcare business Opella to CD&R, marking a significant step in creating a global leader in consumer healthcare.

Information on the Target

Opella has established itself as a leading global player in consumer healthcare, following its recent transition into an independent entity. This marks a significant milestone in the strategic evolution of Sanofi, who has divested a 50% controlling stake in Opella to Clayton, Dubilier & Rice (CD&R) while retaining a notable 48.2% share. The company will also see Bpifrance acquiring a 1.8% stake and joining Opella's Board. The completion of this transaction has garnered approximately €10 billion in total net cash proceeds for Sanofi.

With its headquarters in France, Opella is driven by a vision to innovate and lead in the consumer health sector. The company employs over 11,000 dedicated professionals and operates in 100 countries, relying on 13 state-of-the-art manufacturing sites and four science and innovation development centers. Opella's portfolio encompasses iconic brands, including Allegra, Doliprane, and Dulcolax, positioning it as the third-largest player in the over-the-counter (OTC) and vitamins, minerals, and supplements (VMS) markets globally.

Industry Overview in France

The consumer healthcare industry in France is part of a rapidly growing sector that focuses on the wellness and health of the populace. The increase in health awareness among consumers, coupled with an aging populat